GLP-1R和CK17在甲状腺乳头状癌中的表达及临床意义

摘要

目的 探讨甲状腺乳头状癌组织中胰高血糖素样肽-1受体(GLP-1R)和细胞角蛋白17(CK17)的表达及临床病理意义.方法 采取免疫组织化学及免疫印迹法检测甲状腺正常组织(对照组,n=50)和甲状腺乳头状癌组织(观察组,n=80)中GLP-1R和CK17的表达,并分析二者水平与甲状腺乳头状癌病理因素间的相关性.结果 对照组中22例(44.00％)有GLP-1R蛋白低表达;观察组中77例(96.25％)有GLP-1R蛋白表达,两组比较差异有统计学意义(P＜0.01).对照组中有8例(16.00％)CK17表达阳性;观察组中CK17阳性表达有77例(96.25％),两组比较差异有统计学意义(P＜0.01).GLP-1R的阳性表达与甲状腺乳头状癌的临床病理因素间差异无统计学意义(P＞0.05).CK17表达与甲状腺乳头状癌患者的性别、年龄无明显相关(P＞0.05),而与肿瘤的直径、临床分期及颈部淋巴结转移明显相关(P＜0.05).结论 甲状腺乳头状癌组织中GLP-1R和CK17均高表达,CK17表达与甲状腺乳头状癌的肿瘤直径、临床分期及颈部淋巴结转移明显相关.%Objective To investigate the expressions of glucagon-like peptide-1 receptors (GLP-1R) and cytokeratin17 (CK17) in papillary thyroid cancer tissue and clinicopathological significance.Methods The immunohistochemistry and immunoblotting method were employed to detect the expressions of GLP-1R and CK17 in normal thyroid tissues (control group,50 cases) and papillary thyroid cancer tissue (observation group,80 cases).Then the correlation between the expressions of GLP-1R and CK17 with pathological factors of thyroid cancer was analyzed.Results Low expression of GLP-1R was found in 22 cases (44.00 ％) of the control group,while GLP-1R was expressed in 77 cases(96.25 ％) of the observation group,and the difference between both groups was statistically significant(P＜0.01).The expression of CK17 was positive in 8 cases(16.00％) of the control group,while 77 cases(96.25 ％) in the observation group were CK17 expression positive,and the difference between both groups was statistically significant(P＜0.01).The difference between GLP-1 positive expression and clinicopathologic factors had no statistical significance(P＞0.05).The difference between CK17 expression with sex and age had no statistical significance (P＞0.05),and was obviously related with the tumor diameter,clinical stages and cervical node metastasis of thyroid neoplasms(P＜0.05).Conclusion GLP-1R and CK17 all are highly expressed in papillary thyroid cancer tissue and CK17 expression is obviously related with the tumor diameter,clinical stages and cervical node metastasis of papillary thyroid cancer.